Adirondack Capital Advisors’s Aquestive Therapeutics AQST Stock Holding History

Adirondack Capital Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$55.6K	Hold	12,000	–	–	0.03%	44
2026 Q2	$49.9K	Hold	12,000	–	–	0.03%	45
2026 Q1	$49.8K	Buy	+12,000	New	+$48.7K	0.03%	43

Other funds holding AQST

CCM

Cox Capital Management Andover, Massachusetts $179M AUM 28.94% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Adirondack Capital Advisors's AQST Position: Q3 2026 in Review

Adirondack Capital Advisors held its Aquestive Therapeutics (AQST) position steady in Q3 2026 at 12,000 shares worth $55.6K. The position accounts for 0.03% of the portfolio, ranked #44.

Adirondack Capital Advisors first reported a position in AQST in Q1 2026 and has held it in 3 quarters since. 5 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

Adirondack Capital Advisors held 12,000 shares of Aquestive Therapeutics worth $55.6K as of Q3 2026.
Adirondack Capital Advisors left its Aquestive Therapeutics share count unchanged in Q3 2026.
Aquestive Therapeutics made up 0.03% of Adirondack Capital Advisors's portfolio in Q3 2026, its #44 holding.
Adirondack Capital Advisors first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 3 quarters since.
5 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Adirondack Capital Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.